Contrast agent developer North American Scientific reported fiscal fourth-quarter net sales of $5.1 million, up 11.3% compared with net sales of $4.6 million in the fourth quarter of 2000. For the period (end-October 31), the Chatsworth, CA-based vendor had net income of $94,000, compared with pro forma net income of $1.3 million last year (excluding a $11.4 million charge).
The decline in net income was attributed to ongoing development costs for Apomate, its radiopharmaceutical imaging agent, according to NAS. For the fiscal year, the vendor had net sales of $19.3 million, up 10.6% compared with net sales of $17.5 million last year. NAS had pro forma net income (excluding one-time charge) of $400,000, compared with pro forma net income (excluding one-time charge) of $5.4 million in 2000.
By AuntMinnie.com staff writersDecember 11, 2001
Related Reading
NAS unit begins clinical Apomate trials, November 30, 2001
NAS revenues climb in Q3, August 29, 2001
NAS names Robert Morgan as VP, June 19, 2001NAS taps Jones for Theseus VP post , April 10, 2001
Theseus starts Apomate phase II trials, April 3, 2001
Copyright © 2001 AuntMinnie.com
